- Home
- IMPP vs XFOR Comparison
IMPP vs XFOR Comparison
Compare IMPP & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IMPP | XFOR |
|---|---|---|
| Founded | 1981 | 2014 |
| Country | Greece | United States |
| Employees | 49 | 143 |
| Industry | Marine Transportation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 160.1M | 407.5M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | IMPP | XFOR |
|---|---|---|
| Price | $4.81 | $4.11 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | ★ 501.0K | 391.5K |
| Earning Date | 05-22-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $51.79 | N/A |
| Revenue Next Year | $6.97 | N/A |
| P/E Ratio | $3.68 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.45 | $1.35 |
| 52 Week High | $6.57 | $4.83 |
Technical Indicators
Market Signals| Indicator | IMPP | XFOR |
|---|---|---|
| Relative Strength Index (RSI) | 66.43 | 49.74 |
| Support Level | $4.04 | $3.57 |
| Resistance Level | $4.94 | $4.54 |
| Average True Range (ATR) | 0.17 | 0.22 |
| MACD | 0.04 | -0.02 |
| Stochastic Oscillator | 94.04 | 17.16 |
Price Performance
Historical ComparisonAbout IMPP Imperial Petroleum Inc.
Imperial Petroleum Inc is a provider of international seaborne transportation services to oil producers, refineries, and commodities traders. It owns and operates a fleet of six medium-range product tankers that carry refined petroleum products such as gasoline, diesel, fuel oil, and jet fuel, as well as edible oils and chemicals.
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.